Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Up 5.6% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics Inc. (NTLA) is a biotechnology company focused on developing CRISPR-based gene editing therapies. The company's stock had a strong bullish movement today.

Why is Intellia Therapeutics, Inc. going up?

NTLA stock is up 5.6% on May 22, 2026 14:26

• The dismissal of four counterclaims in the BlueAllele patent infringement lawsuit is seen as a positive development for Intellia Therapeutics, reducing legal uncertainties and potential financial liabilities.
• The submission of the CRISPR-based gene editing therapy, nex-z, poses a unique regulatory challenge for the FDA, highlighting the innovative nature of Intellia's technology and its potential market impact.
• Despite concerns about dilution from a recent equity offering, Intellia's improved net loss in Q1 2026 and emphasis on a multi-year cash runway are reassuring investors about the company's financial stability and ability to execute its gene-editing pipeline.
• Investor focus on Intellia's gene-editing pipeline progress, upcoming clinical trial readouts, and regulatory milestones underscores the market's anticipation of potential breakthroughs in the competitive gene-editing landscape, further boosting confidence in the company's growth prospects.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit

Intellia Therapeutics Inc. has dismissed four counterclaims, including one regarding patent inventorship and claims of tortious interference and unfair trade practices, in BlueAllele Corp.'s gene-editing patent infringement lawsuit. This follows a previous dismissal of Intellia's unjust enrichment counterclaim. The dismissals were granted with prejudice by Judge John F. Murphy in the US District Court for the District of Delaware.

https://news.bloomberglaw.com/ip-law/intellia-dismisses-four-counterclaims-in-blueallele-patent-suit

Intellia’s CRISPR Submission Is a Regulatory Stress Test the FDA Has Never Faced Before

Intellia Therapeutics' submission of its CRISPR-based gene editing therapy, nex-z, presents an unprecedented regulatory challenge for the FDA. Unlike previous gene therapies, nex-z involves a permanent, single-dose genomic edit, raising complex questions about long-term monitoring, off-target risks, and who bears the cost and responsibility for decades of follow-up. The article argues that the FDA's current guidance is not equipped for the unique characteristics of in vivo CRISPR and must evolve to establish a new regulatory architecture for this transformative technology.

https://www.clinicaltrialvanguard.com/opinion/intellias-crispr-submission-is-a-regulatory-stress-test-the-fda-has-never-faced-before/

Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise?

Intellia Therapeutics reported a narrower net loss in Q1 2026, but concerns persist regarding dilution from its recent $180 million equity offering. The company highlights a multi-year cash runway, shifting focus to the execution of its gene-editing pipeline and clinical milestones, particularly the regulatory path for lonvo z. Investors are watching to see if future funding needs can be managed without further significant dilution.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/does-intellia-therapeutics-ntla-cash-runway-truly-offset-dil/amp

Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise?

Intellia Therapeutics reported an improved net loss in Q1 2026 but faces ongoing concerns about dilution following an April equity offering. Despite management's assertion of a multi-year cash runway, investors are closely watching the progress of its gene-editing pipeline, particularly the regulatory path of lonvo-z, to see if future funding needs can be controlled. The article highlights that while the equity raise provides capital, the risk of further dilution remains if cash burn continues at current levels.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/does-intellia-therapeutics-ntla-cash-runway-truly-offset-dil

Intellia Therapeutics stock (US45826J1051): gene-editing pipeline update keeps investors focused on

Intellia Therapeutics continues to attract investor attention as it advances its CRISPR-based gene-editing pipeline. The company focuses on both in vivo and ex vivo approaches to develop one-time treatments for serious diseases, with its financial performance currently driven by collaboration and license agreements rather than product revenue. Investors are closely monitoring upcoming clinical trial readouts, regulatory milestones, and partnership developments to assess the potential of its therapies and navigate the competitive gene-editing landscape.

https://www.ad-hoc-news.de/boerse/news/ueberblick/intellia-therapeutics-stock-us45826j1051-gene-editing-pipeline-update/69353746

Trending Today

Intellia Therapeutics, Inc. Price History

29.03.2026 - NTLA Stock was down 10.0%

• Despite favorable late-stage trial outcomes and starting the FDA submission process for lonvoguran ziclumeran (lonvo-z) for HAE treatment, NTLA witnessed a decline in its stock value.
• The decrease in share price due to a public stock offering priced lower per share raised concerns about potential dilution among investors, impacting the company's stock performance negatively.
• Market sentiment may have been influenced by fears of share dilution from the public offering, overshadowing the encouraging trial results and future potential of gene-editing therapies.
• Investor hesitancy regarding the company's fundraising strategies and their effects on current shareholders prompted selling pressures, despite promising advancements in clinical research.

18.04.2026 - NTLA Stock was down 5.7%

• The recent bearish movement in NTLA stock could be linked to negative insider sentiment, with an increase in share sales by corporate insiders over the past quarter, as noted by a Hold rating and $12.00 price target.
• Despite positive Phase 3 results for lonvo-z and progress on its biologics license application, mixed short-term share price performance and diverse views from analysts may have contributed to the downward pressure on the stock.
• The wide spread in analyst valuations, hinting at uncertainty about the company's growth potential, could have also influenced investors to take a cautious stance, resulting in the bearish movement in NTLA stock.
• In general, while the company's clinical advancements and financial strategy are respected, lingering concerns about valuation and differing views on future growth prospects appear to have impacted the stock performance.

14.04.2026 - NTLA Stock was down 9.8%

• Despite a reduced loss per share in Q1 2026, Intellia Therapeutics (NTLA) witnessed a decline in the market today.
• The company outperformed in earnings but fell short of revenue expectations, potentially influencing negative investor reactions.
• Analysts hold varying perspectives on the company's future, citing worries about sustained losses and the path to profitability that could have impacted the stock price.
• Negative insider sentiment and larger-than-anticipated losses per share in the recent quarter may have contributed to the stock's downturn, notwithstanding optimistic pipeline developments.

14.04.2026 - NTLA Stock was down 5.8%

• NTLA posted a Q1 2026 net loss of $96.2 million, which has sparked worries about its path to profitability and prompted a cautious response from investors.
• While exceeding earnings per share projections, the company fell short on revenue, reporting $15 million, leading to a downward trend in the market.
• The persistent losses, high price-to-sales ratio, and risks of dilution may have contributed to the prevailing bearish sentiment and decline in NTLA shares.
• Despite positive developments in its pipeline, such as successful Phase 3 outcomes for lonvo-z and the lifting of FDA clinical holds for nex-z trials, concerns about financial performance and short-term profitability seem to overshadow these advancements.

01.04.2026 - NTLA Stock was down 5.4%

• Despite successfully raising funds through a public equity offering and filing a Biologics License Application for lonvoguran ziclumeran (lonvo-z) after meeting Phase 3 endpoints, Intellia Therapeutics stock exhibited a bearish trend.
• The market reaction might be linked to investors resorting to profit-taking after having anticipated positive trial results and witnessing a subsequent sell-off as the news had already been factored into the stock price.
• Investor skepticism regarding the commercial potential of lonvo-z in comparison to existing effective therapies may have also influenced the downward movement, as concerns about future revenue generation linger.
• The surge in NTLA shares during pre-market trading following favorable late-stage trial data for lonvo-z possibly led to an overbought situation, causing a correction as traders capitalized on profits, ultimately resulting in the observed bearish movement today.

19.04.2026 - NTLA Stock was down 8.3%

• The recent bearish movement in NTLA's stock may be linked to investor concerns about potential dilution following a recent $180 million equity offering, despite an improved net loss reported in Q1 2026.
• Investors are wary of the possibility of further dilution if current cash burn rates persist, despite Intellia Therapeutics' affirmation of a multi-year cash runway and positive developments in its gene-editing pipeline.
• Market sentiment seems influenced by uncertainties surrounding future funding requirements and the trade-off between benefits from capital raising and risks of dilution, as suggested in recent discussions on the company's valuation and financial performance.
• Despite encouraging results from clinical trials and advancements in regulatory milestones, today's downward movement in the stock price may reflect a broader market reassessment of Intellia Therapeutics' growth prospects and valuation, resulting in a temporary decline in share value.

13.04.2026 - NTLA Stock was up 5.4%

• Despite reporting a significant Q1 loss, Intellia Therapeutics (NTLA) experienced a strong bullish movement in the stock market.
• The bullish movement can be attributed to the company's positive Phase 3 results for lonvo-z in hereditary angioedema (HAE) and the initiation of a rolling BLA submission for a potential U.S. launch in early 2027.
• Investors seem optimistic about Intellia's pipeline progress, including the lifting of FDA clinical holds for nex-z trials in ATTR amyloidosis, which indicates a promising future for the company's gene-editing programs.
• The market may also be reacting positively to Intellia's strategic reductions in R&D spending to focus on lead programs and commercial readiness, signaling a more efficient use of resources for future growth.

22.04.2026 - NTLA Stock was up 5.6%

• The dismissal of four counterclaims in the BlueAllele patent infringement lawsuit is seen as a positive development for Intellia Therapeutics, reducing legal uncertainties and potential financial liabilities.
• The submission of the CRISPR-based gene editing therapy, nex-z, poses a unique regulatory challenge for the FDA, highlighting the innovative nature of Intellia's technology and its potential market impact.
• Despite concerns about dilution from a recent equity offering, Intellia's improved net loss in Q1 2026 and emphasis on a multi-year cash runway are reassuring investors about the company's financial stability and ability to execute its gene-editing pipeline.
• Investor focus on Intellia's gene-editing pipeline progress, upcoming clinical trial readouts, and regulatory milestones underscores the market's anticipation of potential breakthroughs in the competitive gene-editing landscape, further boosting confidence in the company's growth prospects.

30.03.2026 - NTLA Stock was up 10.8%

• NTLA's stock surged after announcing the pricing of a public offering, raising significant gross proceeds and indicating investor confidence in the company's future prospects.
• The successful results of the Phase 3 trial for lonvo-z, Intellia's gene-editing medicine for hereditary angioedema (HAE), played a crucial role in driving up the stock price.
• The initiation of a rolling Biologics License Application submission to the FDA and the anticipation of a potential U.S. launch in the first half of 2027 further fueled positive investor sentiment.
• Overall, the combination of successful trial data, regulatory progress, and strong financial backing contributed to NTLA's bullish market movement today.

11.04.2026 - NTLA Stock was up 5.0%

• The bullish movement in NTLA's stock price can be attributed to the positive anticipation of beating earnings estimates, supported by a history of surpassing EPS estimates in previous quarters.
• The announcement of Intellia's participation in multiple investor conferences and fireside chats may have increased investor confidence in the company's strategic initiatives and future prospects.
• Cathie Wood's ARK Invest increasing its stake in NTLA could have also contributed to the bullish momentum, signaling confidence from a prominent investor in the biotech sector.
• Conflicting valuation metrics may have caused some volatility in the stock price, with investors potentially weighing the undervaluation suggested by the DCF model against the overvaluation indicated by the P/S ratio.

08.04.2026 - NTLA Stock was up 5.9%

• NTLA is expected to beat earnings estimates, with a positive Earnings ESP and a history of surpassing EPS estimates, indicating strong financial performance.
• A major investment firm increased its stake in NTLA, showcasing confidence in the company's future prospects and contributing to positive market sentiment.
• The announcement of NTLA's participation in upcoming investor conferences and positive Phase 3 results for its CRISPR gene editing therapy likely generated excitement among investors, driving the bullish movement in the stock.
• Overall, the combination of favorable financial outlook, increased institutional interest, and positive developments in its therapeutic pipeline propelled NTLA's stock price higher today.

12.04.2026 - NTLA Stock was down 7.0%

• NTLA stock's decline might be linked to the company's Q1 2026 financial figures, indicating a net loss of $96.2 million and lower revenue compared to the previous year.
• Despite achieving Phase 3 milestones for lonvo-z and progressing its gene-editing projects, investors possibly worried about NTLA's financial performance and the recent stock offering for additional funding.
• The difference in valuation assessments, with the DCF model suggesting undervaluation and the P/S ratio hinting at overvaluation, may have contributed to investor uncertainty, influencing the bearish movement.
• Overall, investor sentiment towards NTLA appears guarded today, considering the promise of its gene editing treatments alongside the company's financial struggles and valuation ambiguity.